

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 July 2008 (24.07.2008)

PCT

(10) International Publication Number
WO 2008/087102 A1

(51) International Patent Classification:

C07K 14/285 (2006.01) C07K 14/47 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/EP2008/050290

(22) International Filing Date: 11 January 2008 (11.01.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0700760.2 15 January 2007 (15.01.2007) GB
0701262.8 23 January 2007 (23.01.2007) GB

(71) Applicant (for all designated States except US): **GLAXOSMITHKLINE BIOLOGICALS SA** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLAIS, Normand** [CA/CA]; Glaxosmithkline Biologicals Canada, 525 Cartier Boulevard West, Laval, H7V 3S8 (CA). **MARTIN, Denis** [CA/CA]; Glaxosmithkline Biologicals Canada, 525 Cartier Boulevard West, Laval, H7V 3S8 (CA). **PALMANTIER, Remi, M.** [FR/CA]; Glaxosmithkline Biologicals Canada, 525 Cartier Boulevard West, Laval, H7V 3S8 (CA).

(74) Agents: **LOVATT, Victoria Jayne** et al.; Glaxosmithkline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(54) Title: VACCINE

(57) Abstract: The present invention relates to fusion proteins comprising an antigen derived from the so-called tumour rejection antigen PRAME (also known as DAGE) linked to an immunological fusion partner which provides T helper epitopes, such as, for example protein D from *Haemophilus influenzae* B, fusion partner proteins comprising fragments of protein D, methods for preparing the same and for formulating vaccines and use of the same for treating a range of cancers.

WO 2008/087102 A1